GlassScriptPhysician profile
Sarah Jadin
NPI 1760844732
$3,310.88
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,315 · 2022: $1,996.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $486.16 | 2021-2022 | |
| Vifor Pharma, INC. | $381.13 | 2021-2022 | |
| Horizon Therapeutics Plc | $371.00 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $293.11 | 2021-2022 | |
| Amgen INC. | $276.90 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $262.05 | 2021-2022 | |
| Akebia Therapeutics INC | $256.80 | 2021-2022 | |
| Daiichi Sankyo INC. | $179.85 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $137.39 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $125.00 | 2021 | |
| Currax Pharmaceuticals LLC | $85.99 | 2021-2022 | |
| Novo Nordisk INC | $85.52 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $80.14 | 2021-2022 | |
| Amarin Pharma, INC. | $73.01 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.01 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $52.63 | 2022 | |
| Glaxosmithkline, LLC. | $47.73 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $35.70 | 2022 | |
| Calliditas Therapeutics US INC. | $18.76 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Jadin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.